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Five monoclonal antibodies specific for bovine respiratory syncytial virus were characterized by Western
immunoblotting, radioimmunoprecipitation, and epitope mapping assays. The monoclonal antibodies were
found to be specific for the fusion protein, and there were at least two antigen binding sites, one of which was
neutralizing.
Bovine respiratory syncytial virus (RSV) is a member of
the Paramyxoviridae family and apparently is closely related
to human RSV (2, 3). Bovine RSV now is recognized as a
major contributor to bovine respiratory disease (3). Isolation
and identification of the virus during outbreaks of bovine
respiratory disease have been hampered by the apparent
lability of the virus and by the lack of high-quality diagnostic
reagents (3). Additionally, only one known study has been
directed at the characterization of bovine RSV structural
proteins that induce biologically important antibodies (5).
Antibody to the 90-kDa protein apparently is capable of
neutralizing the virus but does not inhibit syncytia formation
(9). Antibody to the fusion protein is capable of both
neutralizing the virus and inhibiting syncytia formation (8,
10). Five monoclonal antibodies (MAbs) specific for bovine
RSV were produced and partially characterized (Table 1) (6).
Three of the MAbs (8G12, 15C7, 16A12) were isotype
immunoglobulin Gi (IgGl; K), and two (14D3 and 14E3)
were isotype IgG2a (K). MAbs 8G12 and 15C7 (ascites)
inhibited syncytia formation in vitro and exhibited neutral-
izing activity, whereas the remaining three MAbs did not.
All five MAbs reacted with bovine RSV-infected cells by
direct and indirect fluorescent-antibody tests. The objective
of the present study was to further characterize these MAbs
by radioimmunoprecipitation (RIP), Western immunoblot-
ting, and epitope mapping.
Bovine RSV strain 375 was grown in bovine turbinate cells
cultured in HALS medium (GIBCO) supplemented with 50
,ug of gentamicin per ml and 10% horse serum in a 37°C
humidified incubator with 5% CO2. Confluent monolayers
were adsorbed with bovine RSV at a multiplicity of infection
of 1 for 1 h and then refed HALS medium containing
gentamicin. Virus culture fluid was frozen after the cells
formed syncytia and cell lysis was approximately 80%. The
titer of the virus culture fluid ranged from 105-5 to 106.2 50%
tissue culture infective doses per ml of fluid. The virus
culture fluid was clarified of cell debris and concentrated 10
times with an Amicon DC-2 hollow fiber dialyzer-concentra-
tor (10-kDa cutoff) and purified by linear sucrose gradient (20
to 60%) centrifugation in TEN buffer (0.13 M NaCl, 0.001 M
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EDTA, 0.05 M Tris base [pH 7.7]) at 25,000 rpm (114,000 x
g) in a Beckman L8-70M ultracentrifuge with an SW28 rotor
for 18 h. A band with a density of 1.23 g/ml contained the
bovine RSV; this was confirmed by a characteristic cyto-
pathic effect in tissue culture.
To radiolabel bovine RSV, confluent monolayers were
adsorbed with bovine RSV with a multiplicity of infection of
1.0 for 1 h at 37°C in a humidified incubator with 5% CO2.
The inoculum was then removed, and 2 ml ofHALS medium
plus 2% horse serum containing 50 ,uCi of d-[1-_4C]glu-
cosamine hydrochloride (Amersham) was added. One milli-
liter of 2x RIPA buffer (150 mM NaCl, 0.1% sodium dodecyl
sulfate [SDS], 1% Triton X-100, 1% deoxycholate, 10 mM
Tris [pH 7.2]) was added when the cytopathic effect was
approximately 80%. Labeled virus lysate was divided into
aliquots and stored at -70°C.
The MAbs used in this study were prepared as described
by Klucas and Anderson (6). Polyclonal antibodies were
prepared by immunizing a calf with purified bovine RSV
mixed with Freund complete and incomplete adjuvants.
Purified bovine RSV and a negative cell control were
resolved under reducing and nonreducing conditions by
SDS-polyacrylamide gel electrophoresis (PAGE) on 10%
gels (7). Prestained molecular weight markers (Deversified
Biotech) were used to determine the relative mobilities of the
bands. The separated proteins were then transfered to nitro-
cellulose paper (Schleicher & Schuell) in a transblot cell
(Bio-Rad). After transfer, the nitrocellulose was blocked
with RIPA buffer containing 2% bovine serum albumin
(BSA; Sigma) for 30 min at room temperature. The blocked
nitrocellulose was then incubated with MAb or polyclonal
antiserum diluted in phosphate-buffered saline (PBS) with
0.05% Tween 20 plus 1% BSA for 1 h at room temperature
and was then washed three times with PBS-Tween 20.
Alkaline phosphatase-conjugated goat anti-mouse IgG or
goat anti-bovine IgG (Kirkegaard and Perry) diluted in PBS
plus 1% BSA was then added and incubated for 1 h at room
temperature. The nitrocellulose was washed again and de-
veloped with 5-bromo-4-chloro-3-indolyl phosphate and ni-
troblue tetrazolium substrate (Kirkegaard and Perry). One
hundred microliters of labeled virus lysate was preadsorbed
with 50 ,ul of 10% formalin-fixed Staph A (from Staphylo-
coccus aureus Cowen strain) for 1 hour at 4°C, to remove
any material that may have nonspecifically bound to Staph
A, and was then microcentrifuged (Fisher) to remove the
Staph A. Forty-five microliters of monoclonal ascitic fluid
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TABLE 1. Biological activities of MAbs to bovine RSV'
Western blot RIP with
with proteins of proteinsSerum Sy the following fowfth
MAb Isotype neutrali- inhibition IFA the (kDa): followininibtion sz( : size (kDa):
20 46 70 120 20 46
8G12 IgGl + + + - + + + + +
15C7 IgGl + + + - + + + + +
16A12 IgG1 - + - - - + + +
14D3 IgG2a - - + - - - + + +
14E3 IgG2a - - + - - - + + +
a +, positive; -, negative.
b IFA, immunofluorescence assay.
diluted 1:10 in PBS was added to 45 ,ul of the preadsorbed
labeled virus preparation and incubated overnight at 4°C.
Fifty microliters of 10% Staph A was added to the antigen-
antibody mixture and incubated for 1 h at room temperature.
The Staph A-antibody complex was pelleted in a microcen-
trifuge and washed three times with RIPA buffer. After the
final wash, 45 ,ul of 1 x SDS-PAGE sample buffer was added
to the pellet. The sample was then heated to 100°C for 5 min
and centrifuged to remove the Staph A, and 40 p.l was loaded
onto a 10% SDS-polyacrylamide gel. After electrophoresis,
the gels were fixed (40% methanol, 10% acetic acid), soaked
in a scintillant (Ampliphy; Amersham), and dried with a
Bio-Rad gel drier. The dried gels were exposed to X-ray film
(X-Omat; Kodak) and developed by fluorography (4).
Each MAb (8G12, 15C7, 14D3, 14E3, 16A12) was partially
purified by ammonium sulfate precipitation and dialyzed
against 6 liters of 0.1 M NaHCO3 (pH 8.4) for 24 h with two
changes of buffer. The protein concentration of the purified
antibodies was adjusted to 1 mg/ml with 0.1 M NaHCO3. The
MAbs were biotinylated by dissolving 1.0 mg of biotinami-
docaproate N-hydroxysuccinimide ester (Sigma) in 1.0 ml of
dimethyl sulfoxide and immediately adding 200 of the
biotin solution to 1 ml of each of the MAb solutions and
reacting them at room temperature for 2 h. The biotinylated
MAbs were then dialyzed against PBS (pH 7.2) overnight at
4°C with two changes of buffer. The conjugates were diluted
1:2 with glycerol, divided into aliquots, and stored at -20°C.
Competitive interactions among the MAbs were evaluated
by solid-phase enzyme-linked immunosorbent assay
(ELISA) similar to that described by Anderson et al. (1).
Thirty nanograms of purified virus in 100 p.l of coating buffer
(0.01 M sodium borate [pH 9.2]) per well was adsorbed onto
96-well polystyrene plates (Nunc) at 4°C for 18 h. The wells
were emptied, washed three times with PBS-Tween 20, and
blocked with coating buffer containing 2% BSA for 30 min at
37°C. Competition among the MAbs was assayed by simul-
taneous incubation at 37°C of biotinylated MAb with various
concentrations of unlabeled competitor MAb on the antigen-
coated plates. The biotinylated MAb was used at a dilution
that gave the optimum signal-to-noise ratio without the
competing MAb. Plates were then washed with PBS-Tween
20, 100 of steptavidin peroxidase (Kirkegaard and Perry)
in PBS containing 1% BSA (1:4,000) was added to each well,
and the plates incubated for 1 h at 37°C. The plates were
washed as described above; this was followed by the addi-
tion of 2,2'-azino-di(3-ethyl-benzthiazole sulfonate) sub-
strate (Kirkegaard and Perry). The A405 was recorded on a
Dynatech MR650 micro-ELISA Reader after 30 min of
incubation at 37°C. The percent competition was calculated
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FIG. 1. PAGE and Western immunoblotting of purified bovine
RSV. Four micrograms of purified bovine RSV was electrophoresed
under reducing and nonreducing conditions on 10% SDS-polyacryl-
amide gels (not on the same gels), transferred to nitrocellulose, and
probed with MAbs and polyclonal antibodies. Lanes 1 to 3, reducing
conditions; lanes 4 to 9, nonreducing conditions. Lane 1, virus
probed with bovine polyclonal antibodies showing the two subunlts
of the fusion protein VP46 and VP20 along with other virus-specific
proteins; lane 2, virus probed with MAb 8G12 reacting with
VP46(F1); lane 3, virus probed with MAb 15C7 reacting with
VP46(F1); lane 4, virus probed with bovine polyclonal antibodies
showing the dimer (VP120) and monomer (VP69) of the fusion
protein along with other virus-specific proteins; lane 5, virus probed
with MAb 8G12 reacting with VP120 and VP69; lane 6, virus probed
with MAb 15C7 reacting with VP120 and VP69; lane 7, virus probed
with MAb 16A12 reacting with VP120; lane 8, virus probed with
MAb 14D3 reacting with VP120; lane 9, virus probed with MAb
14E3 reacting with VP120. Numbers on the left are molecular
masses, in kilodaltons.
by the following formula: (1 - A/Amax)100, where A is the
mean of the specific absorbance of wells with the competing
MAb, and Amax is the mean of the specific absorbance for
wells with diluent in place of the competing MAb. Compe-
tition was considered significant when the blocking was 50%
or greater.
Results of the analysis by immunoblotting are shown in
Fig. 1. Analysis of purified bovine RSV under nonreducing
conditions with the bovine polyclonal antiserum showed six
proteins (approximately 120, 70, 42, 34, 29, and 22 kDa).
Reducing conditions revealed at least six virus-specific pro-
teins (approximately 46, 42, 34, 29, 25, 22, and 20 kDa); the
120- and 70-kDa proteins disappeared and the 46- and 20-kDa
protein bands stained much more intensely. Western blot
analysis with MAb 8G12 showed activity similar to that of
the polyclonal antiserum with regard to the fusion protein.
Under nonreducing conditions, the MAb identified two
bands (120 and 70 kDa). Under reducing conditions, MAb
8G12 reacted only with one band (46 kDa), suggesting that
the epitope recognized by this MAb is on the 46-kDa subunit
of the fusion protein. This MAb was a neutralizing antibody
(6), indicating that there may be a neutralizing epitope on the
46-kDa subunit of the fusion protein. MAb 15C7 reacted
similarly to MAb 8G12; i.e., under reducing conditions it
reacted with a 46-kDa protein and under nonreducing con-
ditions it reacted with 120- and 70-kDa proteins, but with less
intensity than MAb 8G12 did. MAbs 16A12, 14D3, and 14E3
each reacted with a 120-kDa protein under nonreducing
conditions, but they did not react with any protein under
reducing conditions. RIP with [14C]glucosamine-labeled vi-
rus demonstrated specificity for the fusion protein with all
five MAbs (data not shown). Two bands were evident on the
fluorograms with each MAb; the bands were 46- and 20-kDa
glycoproteins.
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TABLE 2. Competition ELISA with biotinylated and
nonbiotinylated MAbs
Biotinylated % Competition for the following competing MAbsa:
MAb 8G12 15C7 14E3 14D3 16A12
8G12 60 68 4 -3 0
16A12 20 15 10 3 42
15C7 57 82 -2 -5 14
14D3 0 12 10 16 3
14E3 -11 3 7 15 -55
a Percent blocking is indicated for 2.5 Fig of competing MAb, and blocking
of 50% or more was considered significant.
Competition (epitope mapping) data are presented in Ta-
ble 2. At least two, and possibly three, epitopes were
identified by the five MAbs. There was two-way competition
between MAbs 8G12 with 15C7. None of the other MAbs
competed with MAb 8G12 or 15C7. There was weak com-
petition between MAbs 14D3 and 14E3. These two MAbs
did not compete to a high degree with the unbiotinylated
homologous MAb, suggesting that biotinylation of these
MAbs lowers the affinity for their binding sites or indicating
that each MAb had a low affinity for the epitope. Competi-
tion between biotinylated MAbs 14E3 with 16A12 seemed to
enhance the binding of MAb 14E3, suggesting that the
binding of MAb 16A12 alters the protein such that the
epitope is more accessible for MAb 14E3 to bind to. It may
be hypothesized that MAbs 14D3 and 14E3 are specific for a
different epitope than MAbs 8G12 and 15C7 are. MAb 16A12
competed minimally with all other MAbs except MAb 14E3.
When MAb 16A12 was used as the competing antibody, it
competed or at least interfered with the other three biotiny-
lated MAbs. When biotinylated MAb 16A12 was used with
the other nonbiotinylated MAbs, no competition was ob-
served.
A summary of the MAb activities observed in this study is
presented in Table 1. Western blotting activity with the
46-kDa subunit was observed only under reducing condi-
tions. Activity with the 70- and 120-kDa proteins occurred
only under nonreducing conditions. RIP with the MAbs
showed activity only with the 20- and 46-kDa subunits. In
reality, the MAbs probably reacted with the 120- and 70-kDa
proteins, but when the precipitate was put into SDS-PAGE
sample buffer and heated, the protein may have been re-
duced to the subunits. Western blot analysis demonstrated
that the 46-kDa epitope recognized by MAbs 8G12 and 15C7
is stable under denaturing and reducing conditions. How-
ever, epitopes recognized by the remaining MAbs (14D3,
14E3, 16A12) apparently were not stable under these condi-
tions.
All the data indicate that the five MAbs used in this study
are specific for the fusion protein of bovine RSV and that
there are at least two distinct antibody-binding sites on the
fusion protein. On the basis of competition ELISA, RIP, and
Western blotting, an epitope on the fusion protein (46 kDa)
of bovine RSV appears to be responsible for neutralization.
In addition, these studies provide evidence that a diagnostic
assay (ELISA) may be developed with these MAbs; MAb
8G12 would probably be the antibody of choice, since it
appears to be specific for a stable and biologically significant
epitope. Additional MAbs will be useful to further charac-
terize the fusion protein and the other proteins of bovine
RSV.
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